Company News

Five New Abstracts, Poster Presentations Featuring MyoStrain® Presented at European Society of Cardiology Congress 2020

September 8, 2020
Company News

MORRISVILLE, N.C., September 8, 2020 – Myocardial Solutions (“MSI”) technology MyoStrain® was featured in five unique abstracts and e-poster presentations at the European Society of Cardiology (ESC) virtual congress event from August 29th to September 1st.

The abstracts discussed the diagnostic value and clinical impact of MyoStrain for the early detection and management of progressive heart dysfunction across multiple cardiac disease states, describing MyoStrain’s reliability and consistency as a tool for measuring myocardial deformation,[1] MyoStrain rapid detection of cardiomyopathies without the use of contrast agents,[2] MyoStrain’s ability to monitor progressive intra-myocardial dysfunction from arterial hypertension before ejection fraction (EF),[3] as well as to monitor progressive intra-myocardial dysfunction from mitral valvular disease before EF.[4]

Of the five presentations featured, a rapid fire presentation from the PREFECT study (NCT03543228) compared the effectiveness of MyoStrain fast-SENC (f SENC) versus echocardiography (ECHO) for quantifying the cardiotoxic effects of anthracycline-based chemotherapy, evaluating MyoStrain as a proactive monitoring tool to enable cardio-protection for cancer patients undergoing chemotherapy.[5] Results demonstrated the speed and accuracy of MyoStrain to detect early chemotherapy-induced cardiotoxicity independent of cardiovascular compensatory mechanisms, versus ECHO-based EF and global longitudinal strain (GLS), which did not detect sublinical (asymptomatic) cardiotoxicity.

The findings were presented by Dr. Henning Steen, Principal Investigator of the PREFECT study and Head of Cardiac MRI at medneo GmbH in Berlin, Germany, who said: “MyoStrain enabled the early detection of cardiotoxic effects from chemotherapy and individualized cardio-protection without interrupting oncology care. MyoStrain offers cardio-oncologists and oncologists the clinical opportunity to potentially prevent cardiovascular complications and improve outcomes for cancer patients and survivors.”

Dr. Rafael Rivero, M.D., Head of Medical Affairs at Myocardial Solutions commented: “The abstracts presented highlight the sensitivity, accuracy and high reproducibility of MyoStrain to not only quantify intra-myocardial dysfunction, but also to help mitigate progressive cardiac dysfunction by initiating proactive treatment strategies early in the patient’s care.” 

Links to the abstracts & posters presented are available below:

[1] Backhaus S J, et al. Performance of different myocardial tissue tracking algorithms and acquisition-based strain imaging to characterise myocardial pathology. Poster presented at ESC Congress 2020.

[2] Hirschberg K, et al. Contrast-agent free evaluation of cardiomyopathies with T1 mapping and the new fast strain-encoded (fSENC) magnetic resonance imaging. Poster presented at ESC Congress 2020.

[3] Montenbruck M, et al. CMR fast-SENC segmental intramyocardial LV strain monitors decline in heart function before ejection fraction in patients with arterial hypertension. Poster presented at ESC Congress 2020. Watch video.

[4] Montenbruck M, et al. CMR fast-SENC segmental intramyocardial LV strain monitors decline in heart function before ejection fraction in patient with mitral valve disease. Poster presented at ESC Congress 2020.

[5] Steen H, et al. Intramyocardial fast-SENC is less impacted by compensatory mechanisms while monitoring cardiotoxic effects of chemotherapy than echocardiography and conventional CMR: the PREFECT study (NCT03543228). Poster presented at ESC Congress 2020.

Media Contact

Ahmed Osman

About Myocardial Solutions, Inc.

Myocardial Solutions, Inc. (MSI) is a medical technology company working to transform the cardiac and cancer care continuum. Leveraging more than 400 publications in clinical research and development, MSI’s proprietary technology, MyoStrain®, is a 10-minute, non-invasive heart function test providing physicians with sensitive diagnostic markers to support the early assessment and individualized treatment of heart dysfunction. MyoStrain has received FDA-510(k) pre-market clearance, CE-mark certification, and is commercially available in the United States and Europe.

To learn more about MyoStrain, visit or connect with us on LinkedIn and Twitter @myocardialsoln.